PubMed:26018083
Annnotations
CL-cell
| Id | Subject | Object | Predicate | Lexical cue | cl_id |
|---|---|---|---|---|---|
| T1 | 99-105 | Cell | denotes | Type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
| T3 | 114-127 | Cell | denotes | Killer T Cell | http://purl.obolibrary.org/obo/CL:0000794 |
| T4 | 203-209 | Cell | denotes | type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
| T6 | 218-232 | Cell | denotes | killer T cells | http://purl.obolibrary.org/obo/CL:0000794 |
| T7 | 687-702 | Cell | denotes | type I NKT cell | http://purl.obolibrary.org/obo/CL:0000921 |
| T8 | 687-693 | Cell | denotes | type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
| T10 | 757-763 | Cell | denotes | T cell | http://purl.obolibrary.org/obo/CL:0000084 |
| T11 | 776-792 | Cell | denotes | type I NKT cells | http://purl.obolibrary.org/obo/CL:0000921 |
| T12 | 776-782 | Cell | denotes | type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
| T14 | 861-877 | Cell | denotes | type I NKT cells | http://purl.obolibrary.org/obo/CL:0000921 |
| T15 | 861-867 | Cell | denotes | type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
| T17 | 1192-1207 | Cell | denotes | type I NKT cell | http://purl.obolibrary.org/obo/CL:0000921 |
| T18 | 1192-1198 | Cell | denotes | type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
GlyCosmos6-Glycan-Motif-Image
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 42-60 | Glycan_Motif | denotes | Galactosylceramide | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE |
| T2 | 519-537 | Glycan_Motif | denotes | galactosylceramide | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G65889KE |
Glycosmos6-GlycoEpitope
| Id | Subject | Object | Predicate | Lexical cue | glyco_epitope_db_id |
|---|---|---|---|---|---|
| T1 | 42-60 | GlycoEpitope | denotes | Galactosylceramide | http://www.glycoepitope.jp/epitopes/EP0074 |
| T2 | 519-537 | GlycoEpitope | denotes | galactosylceramide | http://www.glycoepitope.jp/epitopes/EP0074 |
GlyCosmos6-Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 42-60 | https://glytoucan.org/Structures/Glycans/G65889KE | denotes | Galactosylceramide |
| T2 | 519-537 | https://glytoucan.org/Structures/Glycans/G65889KE | denotes | galactosylceramide |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-139 | Sentence | denotes | Lipid and Carbohydrate Modifications of α-Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation. |
| T2 | 140-274 | Sentence | denotes | The ability of different glycosphingolipids (GSLs) to activate type I natural killer T cells (NKT cells) has been known for 2 decades. |
| T3 | 275-456 | Sentence | denotes | The possible therapeutic use of these GSLs has been studied in many ways; however, studies are needed in which the efficacy of promising GSLs is compared under identical conditions. |
| T4 | 457-538 | Sentence | denotes | Here, we compare five unique GSLs structurally derived from α-galactosylceramide. |
| T5 | 539-714 | Sentence | denotes | We employed biophysical and biological assays, as well as x-ray crystallography to study the impact of the chemical modifications of the antigen on type I NKT cell activation. |
| T6 | 715-913 | Sentence | denotes | Although all glycolipids are bound by the T cell receptor of type I NKT cells in real time binding assays with high affinity, only a few activate type I NKT cells in in vivo or in vitro experiments. |
| T7 | 914-1090 | Sentence | denotes | The differences in biological responses are likely a result of different pharmacokinetic properties of each lipid, which carry modifications at different parts of the molecule. |
| T8 | 1091-1223 | Sentence | denotes | Our results indicate a need to perform a variety of assays to ascertain the therapeutic potential of type I NKT cell GSL activators. |
Glycan-GlyCosmos
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 42-60 | Glycan | denotes | Galactosylceramide | https://api.glycosmos.org/wurcs2image/latest/png/binary/G65889KE |
| T2 | 519-537 | Glycan | denotes | galactosylceramide | https://api.glycosmos.org/wurcs2image/latest/png/binary/G65889KE |
GlyCosmos-GlycoEpitope
| Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
|---|---|---|---|---|---|
| T1 | 42-60 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | Galactosylceramide | http://www.glycoepitope.jp/epitopes/EP0074 |
| T2 | 519-537 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | galactosylceramide | http://www.glycoepitope.jp/epitopes/EP0074 |
GlyCosmos15-NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 83-88 | OrganismTaxon | denotes | Mouse | 10088|10090 |
| T3 | 93-98 | OrganismTaxon | denotes | Human | 9606 |
GlyCosmos15-CL
| Id | Subject | Object | Predicate | Lexical cue | cl_id |
|---|---|---|---|---|---|
| T1 | 99-105 | Cell | denotes | Type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
| T3 | 114-127 | Cell | denotes | Killer T Cell | http://purl.obolibrary.org/obo/CL:0000794 |
| T4 | 203-209 | Cell | denotes | type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
| T6 | 218-232 | Cell | denotes | killer T cells | http://purl.obolibrary.org/obo/CL:0000794 |
| T7 | 687-702 | Cell | denotes | type I NKT cell | http://purl.obolibrary.org/obo/CL:0000921 |
| T8 | 687-693 | Cell | denotes | type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
| T10 | 757-763 | Cell | denotes | T cell | http://purl.obolibrary.org/obo/CL:0000084 |
| T11 | 776-792 | Cell | denotes | type I NKT cells | http://purl.obolibrary.org/obo/CL:0000921 |
| T12 | 776-782 | Cell | denotes | type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
| T14 | 861-877 | Cell | denotes | type I NKT cells | http://purl.obolibrary.org/obo/CL:0000921 |
| T15 | 861-867 | Cell | denotes | type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
| T17 | 1192-1207 | Cell | denotes | type I NKT cell | http://purl.obolibrary.org/obo/CL:0000921 |
| T18 | 1192-1198 | Cell | denotes | type I | http://purl.obolibrary.org/obo/CL:0004120|http://purl.obolibrary.org/obo/CL:0004138 |
GlyCosmos15-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 121-127 | Body_part | denotes | T Cell | http://purl.obolibrary.org/obo/CL_0000084 |
| T2 | 757-763 | Body_part | denotes | T cell | http://purl.obolibrary.org/obo/CL_0000084 |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-139 | Sentence | denotes | Lipid and Carbohydrate Modifications of α-Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation. |
| T2 | 140-274 | Sentence | denotes | The ability of different glycosphingolipids (GSLs) to activate type I natural killer T cells (NKT cells) has been known for 2 decades. |
| T3 | 275-456 | Sentence | denotes | The possible therapeutic use of these GSLs has been studied in many ways; however, studies are needed in which the efficacy of promising GSLs is compared under identical conditions. |
| T4 | 457-538 | Sentence | denotes | Here, we compare five unique GSLs structurally derived from α-galactosylceramide. |
| T5 | 539-714 | Sentence | denotes | We employed biophysical and biological assays, as well as x-ray crystallography to study the impact of the chemical modifications of the antigen on type I NKT cell activation. |
| T6 | 715-913 | Sentence | denotes | Although all glycolipids are bound by the T cell receptor of type I NKT cells in real time binding assays with high affinity, only a few activate type I NKT cells in in vivo or in vitro experiments. |
| T7 | 914-1090 | Sentence | denotes | The differences in biological responses are likely a result of different pharmacokinetic properties of each lipid, which carry modifications at different parts of the molecule. |
| T8 | 1091-1223 | Sentence | denotes | Our results indicate a need to perform a variety of assays to ascertain the therapeutic potential of type I NKT cell GSL activators. |
GlyCosmos15-Sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-139 | Sentence | denotes | Lipid and Carbohydrate Modifications of α-Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation. |
| T2 | 140-274 | Sentence | denotes | The ability of different glycosphingolipids (GSLs) to activate type I natural killer T cells (NKT cells) has been known for 2 decades. |
| T3 | 275-456 | Sentence | denotes | The possible therapeutic use of these GSLs has been studied in many ways; however, studies are needed in which the efficacy of promising GSLs is compared under identical conditions. |
| T4 | 457-538 | Sentence | denotes | Here, we compare five unique GSLs structurally derived from α-galactosylceramide. |
| T5 | 539-714 | Sentence | denotes | We employed biophysical and biological assays, as well as x-ray crystallography to study the impact of the chemical modifications of the antigen on type I NKT cell activation. |
| T6 | 715-913 | Sentence | denotes | Although all glycolipids are bound by the T cell receptor of type I NKT cells in real time binding assays with high affinity, only a few activate type I NKT cells in in vivo or in vitro experiments. |
| T7 | 914-1090 | Sentence | denotes | The differences in biological responses are likely a result of different pharmacokinetic properties of each lipid, which carry modifications at different parts of the molecule. |
| T8 | 1091-1223 | Sentence | denotes | Our results indicate a need to perform a variety of assays to ascertain the therapeutic potential of type I NKT cell GSL activators. |
GlyCosmos15-Glycan
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 42-60 | Glycan | denotes | Galactosylceramide | https://api.glycosmos.org/wurcs2image/latest/png/binary/G65889KE |
| T2 | 519-537 | Glycan | denotes | galactosylceramide | https://api.glycosmos.org/wurcs2image/latest/png/binary/G65889KE |
GlyCosmos15-GlycoEpitope
| Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
|---|---|---|---|---|---|
| T1 | 42-60 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | Galactosylceramide | http://www.glycoepitope.jp/epitopes/EP0074 |
| T2 | 519-537 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | galactosylceramide | http://www.glycoepitope.jp/epitopes/EP0074 |
NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 83-88 | OrganismTaxon | denotes | Mouse | 10088|10090 |
| T3 | 93-98 | OrganismTaxon | denotes | Human | 9606 |
Anatomy-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 121-127 | Body_part | denotes | T Cell | http://purl.obolibrary.org/obo/CL_0000084 |
| T2 | 757-763 | Body_part | denotes | T cell | http://purl.obolibrary.org/obo/CL_0000084 |